 | Up a level |
Viale, G.; Giobbie-Hurder, A.; Gusterson, B. A.; Maiorano, E.; Mastropasqua, M. G.; Sonzogni, A.; Mallon, E.; Colleoni, M.; Castiglione-Gertsch, M.; Regan, M. M.; Price, K. N.; Brown, R. W.; Golouh, R.; Crivellari, D.; Karlsson, P.; Öhlschlegel, C.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S. (2009). Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of oncology, 21(2), pp. 245-254. Oxford University Press 10.1093/annonc/mdp317
Lorenzo, Gianni; Cole, Bernard F; Panzini, Ilaria; Snyder, Raymond; Holmberg, Stig B; Byrne, Michael; Crivellari, Diana; Colleoni, Marco; Aebi, Stefan; Simoncini, Edda; Pagani, Olivia; Castiglione-Gertsch, Monica; Price, Karen N; Goldhirsch, Aron; Coates, Alan S; Ravaioli, Alberto (2008). Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. Supportive care in cancer, 16(1), pp. 67-74. Berlin: Springer 10.1007/s00520-007-0295-y
Viale, Giuseppe; Regan, Meredith M.; Mastropasqua, Mauro G.; Maffini, Fausto; Maiorano, Eugenio; Colleoni, Marco; Price, Karen N.; Golouh, Rastko; Perin, Tiziana; Brown, R. W.; Kovács, Anikó; Pillay, Komala; Öhlschlegel, Christian; Gusterson, Barry A.; Castiglione-Gertsch, Monica; Gelber, Richard D.; Goldhirsch, Aron; Coates, Alan S. (2008). Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. Journal of the National Cancer Institute JNCI, 100(3), pp. 207-212. Oxford University Press 10.1093/jnci/djm289
Ravaioli, A.; Monti, F.; Regan, M. M.; Maffini, F.; Mastropasqua, M. G.; Spataro, V.; Castiglione-Gertsch, Monica; Panzini, I.; Gianni, L.; Goldhirsch, A.; Coates, A.; Price, K. N.; Gusterson, B. A.; Viale, G. (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of oncology, 19(4), pp. 660-668. Oxford University Press 10.1093/annonc/mdm547
Francis, Prudence; Crown, John; Di Leo, Angelo; Buyse, Marc; Balil, Ana; Andersson, Michael; Nordenskjöld, Bo; Lang, Istvan; Jakesz, Raimund; Vorobiof, Daniel; Gutiérrez, Jorge; Van Hazel, Guy; Dolci, Stella; Jamin, Sophie; Bendahmane, Belguendouz; Gelber, Richard D.; Goldhirsch, Aron; Castiglione-Gertsch, Monica; Piccart-Gebhart, Martine (2008). Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial. Journal of the National Cancer Institute JNCI, 100(2), pp. 121-133. Oxford University Press 10.1093/jnci/djm287
Regan, M. M.; Pagani, O.; Walley, B.; Torrisi, R.; Perez, E. A.; Francis, P.; Fleming, G. F.; Price, K. N.; Thürlimann, B.; Maibach, R.; Castiglione-Gertsch, M.; Coates, A. S.; Goldhirsch, A.; Gelber, R. D. (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Annals of oncology, 19(7), pp. 1231-1241. Oxford University Press 10.1093/annonc/mdn037
Bernhard, J; Zahrieh, D; Castiglione-Gertsch, M; Hürny, C; Gelber, RD; Forbes, JF; Murray, E; Collins, J; Aebi, S; Thürlimann, B; Price, KN; Goldhirsch, A; Coates, AS; International, Breast Cancer Study Group Trial VIII (2007). Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. Journal of clinical oncology, 25(3), pp. 263-70. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.04.5393
Colleoni, M; Gelber, S; Goldhirsch, A; Aebi, S; Castiglione-Gertsch, M; Price, KN; Coates, AS; Gelber, RD; International, Breast Cancer Study Group (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. Journal of clinical oncology, 24(9), pp. 1332-41. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.03.0783
Basser, RL; O'Neill, A; Martinelli, G; Green, MD; Peccatori, F; Cinieri, S; Coates, AS; Gelber, RD; Aebi, S; Castiglione-Gertsch, M; Viale, G; Price, KN; Goldhirsch, A; International, Breast Cancer Study Group (2006). Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. Journal of clinical oncology, 24(3), pp. 370-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.03.5196
Rudenstam, CM; Zahrieh, D; Forbes, JF; Crivellari, D; Holmberg, SB; Rey, P; Dent, D; Campbell, I; Bernhard, J; Price, KN; Castiglione-Gertsch, M; Goldhirsch, A; Gelber, RD; Coates, AS; International, Breast Cancer Study Group (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. Journal of clinical oncology, 24(3), pp. 337-44. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2005.01.5784
Regan, MM; Viale, G; Mastropasqua, MG; Maiorano, E; Golouh, R; Carbone, A; Brown, B; Suurküla, M; Langman, G; Mazzucchelli, L; Braye, S; Grigolato, P; Gelber, RD; Castiglione-Gertsch, M; Price, KN; Coates, AS; Goldhirsch, A; Gusterson, B; International, Breast Cancer Study Group (2006). Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. Journal of the National Cancer Institute JNCI, 98(21), pp. 1571-81. Cary, N.C.: Oxford University Press 10.1093/jnci/djj415
Castiglione-Gertsch, M (2006). Adjuvant treatment of breast cancer: sequence and duration of hormonal therapy. Annals of oncology, 17 Suppl 10, x51-x53. Oxford: Oxford University Press 10.1093/annonc/mdl236
Pestalozzi, BC; Zahrieh, D; Price, KN; Holmberg, SB; Lindtner, J; Collins, J; Crivellari, D; Fey, MF; Murray, E; Pagani, O; Simoncini, E; Castiglione-Gertsch, M; Gelber, RD; Coates, AS; Goldhirsch, A; International, Breast Cancer Study Group (IBCSG) (2006). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of oncology, 17(6), pp. 935-44. Oxford: Oxford University Press 10.1093/annonc/mdl064
Gianni, L; Panzini, I; Li, S; Gelber, RD; Collins, J; Holmberg, SB; Crivellari, D; Castiglione-Gertsch, M; Goldhirsch, A; Coates, AS; Ravaioli, A; International, Breast Cancer Study Group (IBCSG) (2006). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer, 106(3), pp. 505-13. New York, N.Y.: John Wiley & Sons 10.1002/cncr.21651
Goss, Paul E.; Ingle, James N.; Martino, Silvana; Robert, Nicholas J.; Muss, Hyman B.; Piccart, Martine J.; Castiglione, Monica; Tu, Dongsheng; Shepherd, Lois E.; Pritchard, Kathleen I.; Livingston, Robert B.; Davidson, Nancy E.; Norton, Larry; Perez, Edith A.; Abrams, Jeffrey S.; Cameron, David A.; Palmer, Michael J.; Pater, Joseph L. (2005). Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute JNCI, 97(17), pp. 1262-1271. Oxford University Press 10.1093/jnci/dji250
Aebi, S.; Castiglione-Gertsch, M. (2001). High-dose chemotherapy for ovarian cancer: Are we ready to go? Annals of oncology, 12(5), pp. 583-584. Oxford University Press 10.1023/A:1011134312452
Roth, A. D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M. S.; Pagani, O.; Morant, R.; Borner, M. M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch, A. (2000). Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma. Annals of oncology, 11(3), pp. 301-306. Oxford University Press 10.1023/A:1008342013224
Goldhirsch, A.; Coates, A. S.; Castiglione-Gertsch, M.; Gelber, R. D. (1998). New treatments for breast cancer: Breakthroughs for patient care or just steps in the right direction? Annals of oncology, 9(9), pp. 973-976. Oxford University Press 10.1023/A:1008436810268
Borner, M. M.; Castiglione, M.; Bacchi, M.; Weber, Walter; Herrmann, R.; Fey, M. F.; Pagani, O.; Leyvraz, S.; Morant, R.; Pestalozzi, B.; Hanselmann, S.; Goldhirsch, A. (1998). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Annals of oncology, 9(5), pp. 535-541. Oxford University Press 10.1023/A:1008270916325
Goldhirsch, A.; Gelber, R. D.; Castiglione, M.; O'Neill, A.; Thürlimann, B.; Rudenstam, C.-M; Lindtner, J.; Collins, J.; Forbes, J.; Crivellari, D.; Coates, A.; Cavalli, F.; Simoncini, E.; Fey, M. F.; Pagani, O.; Price, K.; Senn, H.-J. (1997). Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Annals of oncology, 8(8), pp. 751-756. Oxford University Press 10.1023/A:1008220301866
Thürlimann, B.; Beretta, K.; Bacchi, M.; Castiglione-Gertsch, M.; Goldhirsch, A.; Jungi, W. F.; Cavalli, F.; Senn, H.-J.; Fey, M.; Löhnert, T. (1996). First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of oncology, 7(5), pp. 471-479. Oxford University Press 10.1093/oxfordjournals.annonc.a010635
